Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery

Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

By Alexandra Pecci • Sept. 6, 2023

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

By Meagan Parrish • Sept. 1, 2023

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Lawmakers are already gunning for more dramatic drug pricing reforms

Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.

By Karissa Waddick • Aug. 31, 2023

Medicare named the first 10 drugs up for negotiation. Now what?

The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

By Karissa Waddick • Aug. 30, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’

FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages. 

By Karissa Waddick • Aug. 25, 2023

‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.

By Michael Gibney • Aug. 24, 2023

Henrietta Lacks’ immortal cells put biopharma profits under a microscope

The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

By Michael Gibney • Aug. 23, 2023

Brii Biosciences aims to come up big where Sage and Biogen fell short

The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

By Kelly Bilodeau • Aug. 21, 2023

Behind Flagship Pioneering’s triumphs and tribulations

From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.

By Karissa Waddick • Aug. 18, 2023

Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine

The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.

By Kelly Bilodeau • Aug. 14, 2023

Pharma’s rare disease rush

Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?

By Meagan Parrish , Karissa Waddick • Aug. 14, 2023

5 minutes with — Lundbeck CEO Dr. Deborah Dunsire

The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.

By Meagan Parrish • Aug. 11, 2023

Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth

July’s announcement from the beleaguered drugmaker signals the kind of shift the industry could see more of as M&A and IPOs tick up once again.

By Michael Gibney • Aug. 10, 2023

Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers

The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.

By Taren Grom and Meagan Parrish • Aug. 9, 2023

Pharma’s rocky love affair with oxytocin

Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat migraines, anxiety and more.

By Kelly Bilodeau • Aug. 7, 2023

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

By Karissa Waddick • Aug. 7, 2023

A pioneering approach to biotherapeutic antibody discovery

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous.

By Kimberley Bryon-Dodd, PhD • Aug. 7, 2023

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

By Michael Gibney • Aug. 3, 2023

Is the COVID-19 market crashing?

Pfizer’s recent earnings report could foretell major trouble in the market for pandemic products.

By Meagan Parrish • Aug. 3, 2023

How CymaBay overcame a NASH failure for another shot at liver disease success

The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

By Michael Gibney • Aug. 2, 2023

Biosimilar makers split strategies in bid to take on top-selling Humira

In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

By Jonathan Gardner • July 26, 2023

Biogen’s layoffs are the latest in an industrywide slip

Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.

By Karissa Waddick • July 26, 2023

In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets

Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.

By Alexandra Pecci • July 25, 2023

A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

By Taren Grom and Meagan Parrish • July 20, 2023